The majority of cancer patients today are diagnosed and treated outside the context of clinical research—that is, in the real world.
To improve the efficiency, efficacy, and cost of clinical trials, pharmaceutical companies are using real-world data at each stage of the drug development process.
QIAGEN’s Real-World Insights (RWI) portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to optimize biomarker discovery, maximize trial success, and shorten drug development timelines.